Associated tags: Obstructive sleep apnea, Sleep, Patient, Sleep apnea, Pharmaceutical industry, OSA, Pharmaceutical, Health, Biotechnology, Clinical Trials, CPAP, Quality of life, Stroke
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the 23rd Annual Needham Virtual Healthcare Conference taking place virtually on April 8-11, 2024.
Key Points:
- CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the 23rd Annual Needham Virtual Healthcare Conference taking place virtually on April 8-11, 2024.
- Apnimed’s management will participate in a fireside chat on April 10 from 12:45 pm to 1:25 pm ET and will be available for one-on-one virtual meetings during the conference.
- Investors can view the webcast of the presentation using this link .
- A replay will be available after the conference on the Apnimed website events page.
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Leerink Partners Global Biopharma Conference taking place in Miami on March 11-13, 2024.
Key Points:
- CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Leerink Partners Global Biopharma Conference taking place in Miami on March 11-13, 2024.
- Apnimed’s management will host one-on-one meetings at the conference on March 11, 2024.
Retrieved on:
Thursday, February 22, 2024
CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Evercore ISI 2024 Emerging Biotech Conference taking place virtually on February 28-29, 2024.
Key Points:
- CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, today announced the company will participate in the Evercore ISI 2024 Emerging Biotech Conference taking place virtually on February 28-29, 2024.
- Apnimed’s management will participate in a fireside chat on Thursday, February 29, 2024, from 2:50 pm - 3:20 pm ET.
- Investors should contact their local sales representative for more details about conference registration.
Hamline University,
Sleep,
Ted Harding,
Patient,
Migraine,
Therapy,
COVID-19,
Neurology,
Obstructive sleep apnea,
Culture,
Standard of care,
University,
Commercial,
Wake Forest University,
Pfizer,
MBA,
Acquisition,
Cornell University,
Boehringer Ingelheim,
Telecommunications,
Merck,
SVP,
Growth,
Pharmaceutical industry The addition of Goodrich and Harding are critical new hires as Apnimed prepares to launch AD109 (aroxybutynin/atomoxetine), a potential nighttime oral treatment currently in Phase 3 that could transform the treatment paradigm for millions of OSA patients.
Key Points:
- The addition of Goodrich and Harding are critical new hires as Apnimed prepares to launch AD109 (aroxybutynin/atomoxetine), a potential nighttime oral treatment currently in Phase 3 that could transform the treatment paradigm for millions of OSA patients.
- Graham Goodrich has an extensive track record of commercial success in launching and marketing transformative brands.
- After a successful launch and achieving category leadership, Pfizer acquired the Biohaven Migraine franchise assets and capabilities in October 2022 for $11.6 billion.
- I’m excited to help further develop a company that will have such a profound impact on the lives of OSA patients,” Harding said.
Retrieved on:
Thursday, December 21, 2023
CAMBRIDGE, Mass., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, today announced the first patient dosed in its SynAIRgy Phase 3 study designed to examine the efficacy and safety of AD109 (aroxybutynin/atomoxetine) compared to placebo at six-months. AD109 has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy.
Key Points:
- AD109 has the potential to be the first nighttime oral pharmacologic treatment for people with OSA who are either intolerant of or refuse to use positive airway pressure (PAP) therapy.
- “These trials are a major step in developing a potential treatment that meets the needs of patients who have limited or no other options.
- Based on the results, AD109 has the potential to be a major advance in how we treat OSA.
- Topline results from the Phase 3 program of AD109 are expected in the first half of 2025.”
Apnimed will present from 1:50-2:20 PM ET and management will participate in 1x1 meetings.
Key Points:
- Apnimed will present from 1:50-2:20 PM ET and management will participate in 1x1 meetings.
- 6th Annual Evercore ISI HealthCONx Conference: November 29, 2023, taking place in Miami, FL.
- Apnimed will participate in a fireside chat from 8:45-9:15 AM ET and management will participate in 1x1 meetings.
- Investors should contact their local sales representative for more details about conference registration and scheduling 1x1 meetings.
Retrieved on:
Wednesday, November 1, 2023
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat obstructive sleep apnea (OSA) and other sleep disorders.
Key Points:
- CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat obstructive sleep apnea (OSA) and other sleep disorders.
- The newly formed joint venture, Shionogi-Apnimed Sleep Science, LLC, initially focuses on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of OSA.
- The joint venture is owned equally by Apnimed and Shionogi.
- “Apnimed and Shionogi look forward to working together to transform the treatment of sleep apnea.
Retrieved on:
Wednesday, October 18, 2023
CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that recent data on AD109 (aroxybutynin/atomoxetine) will be featured in an oral presentation at World Sleep 2023 symposium in Rio de Janeiro, Brazil.
Key Points:
- CAMBRIDGE, Mass., Oct. 18, 2023 (GLOBE NEWSWIRE) -- Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, announced that recent data on AD109 (aroxybutynin/atomoxetine) will be featured in an oral presentation at World Sleep 2023 symposium in Rio de Janeiro, Brazil.
- AD109 is a potential first-in-class, novel pharmacologic that is specifically designed to target the key neurological pathways in OSA that activate upper airway dilator muscles to maintain an open airway during sleep.
- It is currently in Phase 3 clinical trials.
- “People with obstructive sleep apnea from around the world need a safe and effective oral medication that can be taken at bedtime to address the underlying biology of the disorder,” said Larry Miller, MD, Chief Executive Officer of Apnimed.
Retrieved on:
Wednesday, October 11, 2023
CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will be participating in the following investor conferences in October 2023:
Key Points:
- CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109, announced today the company will be participating in the following investor conferences in October 2023:
3rd Annual Needham Private Biotech Company Virtual 1×1 Forum: October 17, 2023.
- Leerink Biopharma Private Company Connect (Virtual): October 25, 2023.
- Apnimed management will be hosting one-on-one meetings for those investors attending each conference.
- Investors should contact their local sales representative for more details about registration and scheduling.
Retrieved on:
Tuesday, October 10, 2023
BMI,
Nursing care plan,
Xerostomia,
Food,
Female,
AJRCCM,
Desaturation,
American Journal,
American Journal of Respiratory and Critical Care Medicine,
Confusional arousals,
ST,
AHI,
Safety,
Nausea,
Insomnia,
CPAP,
Hypopnea,
Fatigue,
Research,
Obstructive sleep apnea,
Sleep,
Regulation of food and dietary supplements by the U.S. Food and Drug Administration,
Critical Care Medicine (journal),
IQR,
Sleep apnea,
Șaeș,
Patient,
Apnea–hypopnea index,
Pharmaceutical industry,
Medical imaging AD109 has the potential to be the first-in-class oral treatment for people with mild, moderate and severe OSA.
Key Points:
- AD109 has the potential to be the first-in-class oral treatment for people with mild, moderate and severe OSA.
- The study met its primary endpoint, reduction in Apnea-Hypopnea Index (AHI4, 4% desaturation definition for hypopneas).
- There were no serious adverse events (SAEs) and no new or unexpected adverse events in the MARIPOSA trial.
- There were no serious adverse events (SAEs) and no new or unexpected adverse events in the MARIPOSA trial.
